NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
11.36
-0.03 (-0.26%)
At close: Feb 20, 2026, 4:00 PM EST
11.33
-0.03 (-0.26%)
After-hours: Feb 20, 2026, 7:59 PM EST
NovoCure Employees
NovoCure had 1,488 employees as of December 31, 2024. The number of employees increased by 35 or 2.41% compared to the previous year.
Employees
1,488
Change (1Y)
35
Growth (1Y)
2.41%
Revenue / Employee
$431,632
Profits / Employee
-$119,388
Market Cap
1.27B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,488 | 35 | 2.41% |
| Dec 31, 2023 | 1,453 | 133 | 10.08% |
| Dec 31, 2022 | 1,320 | 153 | 13.11% |
| Dec 31, 2021 | 1,167 | 144 | 14.08% |
| Dec 31, 2020 | 1,023 | 241 | 30.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AdaptHealth | 10,500 |
| Enovis | 7,367 |
| QuidelOrtho | 6,600 |
| Integra LifeSciences Holdings | 4,396 |
| CONMED | 3,900 |
| Tandem Diabetes Care | 2,650 |
| Inspire Medical Systems | 1,333 |
| PROCEPT BioRobotics | 756 |
NVCR News
- 9 days ago - NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching - Seeking Alpha
- 9 days ago - This Biotech Stock Is Jumping 25% After Getting an FDA Boost - Barrons
- 9 days ago - What's Happening With NovoCure Stock? - Forbes
- 10 days ago - Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar - WSJ
- 10 days ago - U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer - Business Wire
- 5 weeks ago - NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update - Business Wire
- 7 weeks ago - NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy - Seeking Alpha